<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00068315</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00044</org_study_id>
    <secondary_id>NCI-2009-00044</secondary_id>
    <secondary_id>ICC 3402</secondary_id>
    <secondary_id>CDR0000321394</secondary_id>
    <secondary_id>ICC 3402</secondary_id>
    <secondary_id>6126</secondary_id>
    <secondary_id>U01CA062502</secondary_id>
    <nct_id>NCT00068315</nct_id>
  </id_info>
  <brief_title>Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase I Trial of PS-341 and Fludarabine for Relapsed and Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of bortezomib when given&#xD;
      together with fludarabine with or without rituximab in treating patients with relapsed or&#xD;
      refractory indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia. Bortezomib may&#xD;
      stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.&#xD;
      Drugs used in chemotherapy, such as fludarabine, work in different ways to stop cancer cells&#xD;
      from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can&#xD;
      block cancer growth in different ways. Some block the ability of cancer cells to grow and&#xD;
      spread. Others find cancer cells and help kill them or carry cancer-killing substances to&#xD;
      them. Giving bortezomib together with fludarabine with or without rituximab may kill more&#xD;
      cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the safety and toxicity of bortezomib and fludarabine with or without rituximab&#xD;
      in patients with relapsed or refractory indolent non-Hodgkin's lymphoma or chronic&#xD;
      lymphocytic leukemia.&#xD;
&#xD;
      II. Determine the maximum tolerated dose of bortezomib in combination with fludarabine in&#xD;
      these patients.&#xD;
&#xD;
      III. Determine the biological effect of this regimen on apoptotic markers, cell cycle kinase&#xD;
      inhibitors, and DNA repair in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of bortezomib.&#xD;
&#xD;
      Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and fludarabine IV&#xD;
      over 30 minutes on days 1-3 or 1-5. Patients may also receive rituximab IV over 1 hour on day&#xD;
      1. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression&#xD;
      or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of bortezomib&#xD;
      until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose&#xD;
      preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then&#xD;
      annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) assessed by Common Toxicity Criteria version 2.0</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue</condition>
  <condition>Hematopoietic/Lymphoid Cancer</condition>
  <condition>Nodal Marginal Zone B-cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <condition>Splenic Marginal Zone Lymphoma</condition>
  <condition>Waldenstr√∂m Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Treatment (bortezomib, fludarabine, rituximab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and fludarabine IV over 30 minutes on days 1-3 or 1-5. Patients may also receive rituximab IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Cohorts of 3-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (bortezomib, fludarabine, rituximab)</arm_group_label>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>VELCADE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (bortezomib, fludarabine, rituximab)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (bortezomib, fludarabine, rituximab)</arm_group_label>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 monoclonal antibody</other_name>
    <other_name>Mabthera</other_name>
    <other_name>MOAB IDEC-C2B8</other_name>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of chronic lymphocytic leukemia (CLL) OR indolent non-Hodgkin's lymphoma&#xD;
             (NHL) of any of the following subtypes:&#xD;
&#xD;
               -  Follicular lymphoma:&#xD;
&#xD;
                    -  Grade I follicular small cleaved cell;&#xD;
&#xD;
                    -  Grade II follicular mixed cell;&#xD;
&#xD;
                    -  Grade II follicular large cell;&#xD;
&#xD;
                    -  Diffuse small cleaved cell;&#xD;
&#xD;
                    -  Small lymphocytic lymphoma;&#xD;
&#xD;
                    -  Lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia)&#xD;
&#xD;
          -  AND&#xD;
&#xD;
               -  Extranodal marginal zone B-cell lymphoma (mucosa-associated lymphoid tissue&#xD;
                  [MALT] lymphoma);&#xD;
&#xD;
               -  Nodal marginal zone B-cell lymphoma (monocytoid B-cell lymphoma);&#xD;
&#xD;
               -  Splenic marginal zone lymphoma (splenic lymphoma with villous lymphocytes);&#xD;
&#xD;
               -  Mantle cell lymphoma:&#xD;
&#xD;
                    -  No blastic phase mantle cell lymphoma&#xD;
&#xD;
          -  Relapsed or refractory, progressive disease:&#xD;
&#xD;
               -  First, second, or third relapse&#xD;
&#xD;
          -  Measurable disease, meeting 1 of the following criteria:&#xD;
&#xD;
               -  At least 1 unidimensionally measurable lesion at least 20 mm by conventional&#xD;
                  techniques OR at least 10 mm by spiral CT scan (for NHL patients);&#xD;
&#xD;
          -  OR:&#xD;
&#xD;
               -  Lymphocytosis &gt; 50,000/mm3 OR evidence of progressive bone marrow infiltration&#xD;
                  failure (e.g., hemoglobin 10 g/dL) OR thrombocytopenia (i.e., platelet count &lt;&#xD;
                  100,000/mm3) with &gt; 30% infiltration of bone marrow by leukemia (for CLL&#xD;
                  patients)&#xD;
&#xD;
          -  No measurable lymphadenopathy (for CLL and Waldenstrom's macroglobulinemia patients)&#xD;
&#xD;
          -  No evidence of CNS lymphoma&#xD;
&#xD;
          -  Performance status:&#xD;
&#xD;
               -  ECOG 0-2&#xD;
&#xD;
          -  Life expectancy:&#xD;
&#xD;
               -  More than 12 weeks&#xD;
&#xD;
          -  No history of uncontrolled orthostatic hypotension&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No uncontrolled concurrent illness&#xD;
&#xD;
          -  No grade 2 or greater neuropathy&#xD;
&#xD;
          -  No history of allergy or anaphylaxis to mannitol, bortezomib, fludarabine, or boron&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  At least 4 weeks since prior monoclonal antibody (MoAB) therapy:&#xD;
&#xD;
               -  Patients who have received MoAB therapy within the past 3 months must have&#xD;
                  documented disease progression since receiving this therapy&#xD;
&#xD;
          -  No prior allogeneic stem cell transplantation&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  Prior fludarabine allowed&#xD;
&#xD;
          -  At least 1 week since prior steroids&#xD;
&#xD;
          -  At least 3 months since prior radio-immunotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior bortezomib&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 75,000/mm3 (greater than 50,000/mm3 if lymphomatous bone&#xD;
             marrow involvement is present)&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  AST/ALT no greater than 4 times normal&#xD;
&#xD;
          -  Creatinine clearance greater than 40 mL/min&#xD;
&#xD;
          -  No other concurrent investigational agents or treatments for the malignancy&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
          -  OR:&#xD;
&#xD;
        Quantitation of IgM paraprotein (for Waldenstrom's macroglobulinemia patients)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brenda Cooper</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Western Reserve University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest General Health Center Ireland Cancer Center</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UHHS-Chagrin Highlands Medical Center</name>
      <address>
        <city>Orange Village</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Suburban Medical Center</name>
      <address>
        <city>South Euclid</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UHHS-Westlake Medical Center</name>
      <address>
        <city>Westlake</city>
        <state>Ohio</state>
        <zip>44145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>September 10, 2003</study_first_submitted>
  <study_first_submitted_qc>September 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2003</study_first_posted>
  <last_update_submitted>September 27, 2013</last_update_submitted>
  <last_update_submitted_qc>September 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

